Alterations of specific biomarkers of metabolic pathways in vascular tree from patients with Type 2 diabetes

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Rosa, Bernal Lopez M ^a,d   Vicenta, Llorente Cortes ^b   Victor, Gomez Carrillo ^c   Dolores, Lopez Carmona ^c   Fernando, Calleja ^c   Ricardo, Gomez Huelgas ^c,d   Lina, Badimon ^b,d   J, Tinahones F ^a,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Atherosclerosis; Glycemic control; Metabolic pathways; Type 2 diabetes mellitus; Vascular system

Indexed keywords

BIOLOGICAL MARKER; CD83 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; HEMOGLOBIN A1C; MESSENGER RNA; PROTEIN BCL 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TOLL LIKE RECEPTOR 2;

ADULT; AGED; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BCL2 GENE; BLOOD VESSEL; BLOOD VESSEL BIOPSY; CD83 GENE; CDKN1A GENE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; COX2 GENE; F3 GENE; FEMALE; FEMORAL VEIN; GENE; GENE EXPRESSION; GLYCEMIC CONTROL; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; INTERNAL MAMMARY ARTERY; ISCHEMIC CARDIOMYOPATHY; LIPID METABOLISM; LRP1 GENE; MALE; MMP2 GENE; MMP9 GENE; MONOCYTE; NDUFA GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; REAL TIME POLYMERASE CHAIN REACTION; SREBP2 GENE; THROMBOSIS; TIMP1 GENE; TIMP3 GENE; TLR2 GENE;

AGED; AGED, 80 AND OVER; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; BIOPSY; CONSTRICTION, PATHOLOGIC; DIABETES MELLITUS, TYPE 2; FEMALE; FEMORAL VEIN; GENE EXPRESSION REGULATION; GENETIC MARKERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; LINEAR MODELS; MALE; MAMMARY ARTERIES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; RNA, MESSENGER; SPAIN;

EID: 84865381080     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-86     Document Type: Article

References (35)

1. Suarez Munguia PJ. Release of nitric oxide induced by blood flow. Update and perspectives of research. Arch Inst Cardiol Mex 2000, 70(2):197-202.
2. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997, 126(8):638-644.
3. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011, 91(1):327-387. 10.1152/physrev.00047.2009, 21248169.
4. Patel RS, Al Mheid I, Morris AA, Ahmed Y, Kavtaradze N, Ali S, Dabhadkar K, Brigham K, Hooper WC, Alexander RW, Jones DP, Quyyumi AA. Oxidative stress is associated with impaired arterial elasticity. Atherosclerosis 2011, 218(1):90-95. 10.1016/j.atherosclerosis.2011.04.033, 21605864.
5. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473(7347):317-325. 10.1038/nature10146, 21593864.
6. Martinet W, Schrijvers DM, De Meyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol 2011, May 25. [Epub ahead of print].
7. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä K, . DECODE Study Group European Diabetes Epidemiology Group Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004, 47(12):2118-2128. DECODE Study Group.
8. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131):854-865. Erratum in: Lancet 1998; 352 (9139): 1558, UK Prospective Diabetes Study (UKPDS) Group.
9. Bernal-Lopez MR, Llorente-Cortes V, Mayas MD, Lopez Carmona D, Gomez-Huelgas R, Badimon L, Tinahones FJ. Modulation of human monocyte CD36 by Type 2 Diabetes Mellitus and other atherosclerotic risk factors. Eur J Clin Invest 2011, 41(8):854-862. 10.1111/j.1365-2362.2011.02475.x, 21668445.
10. Karoly ED, Li Z, Dailey LA, Hyseni X, Huang YC. Up-regulation of tissue factor in human pulmonary artery endothelial cells after ultrafine particle exposure. Environ Health Perspect 2007, 115(4):535-540. 10.1289/ehp.9556, 1852686, 17450221.
11. Heo SH, Cho CH, Kim HO, Jo YH, Yoon KS, Lee JH, Park JC, Park KC, Ahn TB, Chung KC, Yoon SS, Chang DI. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol 2011, 7(2):69-76. 10.3988/jcn.2011.7.2.69, 3131541, 21779294.
12. Ganea E, Trifan M, Laslo AC, Putina G, Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007, 35:689-691. 10.1042/BST0350689, 17635123.
13. Zhou S, Feely J, Spiers JP, Mahmud A. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens 2007, 21(11):861-867. 10.1038/sj.jhh.1002244, 17581602.
14. Dey NB, Lincoln TM. Possible involvement of Cyclic-GMP-dependent protein kinase on matrix metalloproteinase-2 expression in rat aortic smooth muscle cells. Mol Cell Biochem 2012, -May 23. [Epub ahead of print].
15. Razny U, Kiec-Wilk B, Wator L, Polus A, Dyduch G, Solnica B, Malecki M, Tomaszewska R, Cooke JP, Dembinska-Kiec A. Increased nitric oxide availability high fat diet metabolic alterations and gene expression associated with insulin resistance. Cardiovasc Diabetol 2011, 10:68. 10.1186/1475-2840-10-68, 3212914, 21781316.
16. Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF. Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 2001, 156:119-125. 10.1016/S0021-9150(00)00638-9, 11369004.
17. Llorente-Cortes V, Otero-Viñas M, Sanchez S, Rodriguez C, Badimon L. Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. Circulation 2002, 106(24):3104-3110. 10.1161/01.CIR.0000041434.28573.0B, 12473559.
18. Sendra J, Llorente-Cortés V, Costales P, Huesca-Gómez C, Badimon L. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Cardiovasc Res 2008, 78(3):581-589. 10.1093/cvr/cvn043, 18281370.
19. Llorente-Cortes V, Martínez-Gonzalez J, Badimon L. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000, 20(6):1572-1579. 10.1161/01.ATV.20.6.1572, 10845874.
20. Hiltunen TP, Luoma JS, Nikkari T, Ylä-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998, 97(11):1079-1086. 10.1161/01.CIR.97.11.1079, 9531255.
21. Llorente-Cortes V, Otero-Viñas M, Berrozpe M, Badimon L. Intracellular lipid accumulation, low-density lipoprotein receptor-related protein expression, and cell survival in vascular smooth muscle cells derived from normal and atherosclerotic human coronaries. Eur J Clin Invest 2004, 34(3):182-190. 10.1111/j.1365-2362.2004.01316.x, 15025676.
22. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116(11):3015-3025. 10.1172/JCI28898, 1616196, 17053832.
23. Carmody RJ, Chen YH. Nuclear factor-kappaB: activation and regulation during toll-like receptor signaling. Cell Mol Immunol 2007, 4(1):31-41.
24. Skov V, Knudsen S, Olesen M, Hansen ML, Rasmussen LM. Global gene expression profiling displays a network of dysregulated genes in non atherosclerotic arterial tissue from patients with type-2 diabetes. Cardiovasc Diabetol 2012, 11:15. 10.1186/1475-2840-11-15, 3348024, 22340758.
25. Xie X, Liao H, Dang H, Pang W, Guan Y, Wang X, Shyy JY, Zhu Y, Sladek FM. Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs. Mol Endocrinol 2009, 23(4):434-443. 10.1210/me.2007-0531, 2667705, 19179483.
26. Bernal-Lopez MR, Llorente-Cortes V, Gomez-Huelgas R, Badimon L, Tinahones FJ. Intimate relation between genic expression of scavenger receptor CD36 and SREBP2. Proc Biochem 2010, 45(6):1002-1006.
27. Sampson MJ, Davies IR, Braschi S, Ivory K, Hughes DA. Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. Atherosclerosis 2003, 167:129-134. 10.1016/S0021-9150(02)00421-5, 12618277.
28. Redondo S, Ruiz E, Gordillo-Moscoso A, Navarro-Dorado J, Ramajo M, Rodríguez E, Reguillo F, Carnero M, Casado M, Tejerina T. Overproduction of cyclo-oxygenase-2 (COX-2) is involved in the resistance to apoptosis in vascular smooth muscle cells from diabetic patients: a link between inflammation and apoptosis. Diabetologia 2011, 54(1):190-199. 10.1007/s00125-010-1947-x, 20957341.
29. Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res 2008, 58(3-4):247-256.
30. Game BA, He L, Jarido V, Nareika A, Jaffa AA, Lopes-Virella MF, Huang Y. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis 2007, 192(1):85-91. 10.1016/j.atherosclerosis.2006.06.025, 16901490.
31. Ewart MA, Kennedy S. AMPK and vasculoprotection. Pharmacol Ther 2011, 131(2):242-253. 10.1016/j.pharmthera.2010.11.002, 21111758.
32. Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Schwab U, Eriksson JG, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M. Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individual with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Cardiovasc Diabetol 2011, 10:83. 10.1186/1475-2840-10-83, 3196906, 21943112.
33. Ewart MA, Kennedy S. Diabetic cardiovascular disease?. AMP-activated protein kinase (AMPK) as a therapeutic target. Cardiovasc Hematol Agents Med Chem 2012, [Epub ahead of print].
34. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
35. Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008, 358:2630-2633. 10.1056/NEJMe0804182, 18539918.